Built for cell therapy R&D
One structured workspace for experiments, samples and analysis. Every step is an exact entry, so CAR-T, iPSC and MSC programs stay traceable from discovery to IND.
CAR-T-07 · Autologous · FMC63 scFv, 4-1BB/CD3ζ · Lentiviral
5.6×10⁸ viable cells, 95.1% viability. Fresh medium with IL-7 and IL-15, 10 ng/mL each.
Lentiviral vector LV-CD19-BBζ, MOI 3. Vector washed out after 24 h.
CD4/CD8 selected from LP-112. 1.0×10⁸ cells at 1×10⁶/mL, CD3/CD28 beads 1:1.
Seeding density 2.0×10⁶2.5×10⁶
Reason: Protocol v3.2 amendmentELN entry signed e-signature
Protocol v3.2 locked locked
Changes need a signed reason.
The BioPilot platform
Every material, step and result is an exact entry from one shared vocabulary, not free text. That is what makes runs comparable, models possible and regulatory evidence quick to assemble.
Plan experiments from exact building blocks: cell lines, reagent lots, media and instruments from your own inventory, on stage-by-day protocols.
Gate flow data, run scRNA-seq and model your process inside the record, so every result sits next to the conditions that produced it.
Lineage from donor or master cell bank to the final study, with audit trails and e-signatures captured as you work, not rebuilt before an IND or CTA.
Solutions
The stages, assays and quality attributes of each modality come built in, so every run is recorded the same way and stays comparable with the last.
CAR-T · CAR-NK
Autologous and allogeneic process development, from starting material to release testing.
Cardiomyocytes · β-cells · neurons and more
Banked lines, edits and stage-by-day differentiations with their media and small molecules.
Bone marrow · adipose · umbilical cord
Passage-by-passage expansion with the identity panel and potency assays MSC programs report.
BioPilot is built for both regenerative medicine and immune cell therapy R&D: iPSC differentiation, MSC expansion, CAR-T and CAR-NK process development, and gene-modified and viral-vector workflows. Stages, media, markers and assays for these processes come pre-configured, so every run is recorded the same way and stays comparable.
Both. BioPilot combines an electronic lab notebook (ELN), a LIMS for samples, reagents, media, equipment and cell banks, a protocol builder, and built-in analysis including flow cytometry gating, scRNA-seq pipelines and Bayesian optimization. Every record is linked, from master cell bank through in vitro experiments to in vivo studies.
Benchling is a general-purpose R&D platform used across many modalities and configured to each team's workflows. BioPilot is built only for cell therapy: stage-by-day protocols, MCB/WCB cell bank genealogy, flow cytometry gating linked to CQAs and in vivo study tracking are part of the core product rather than something each team configures. If your team runs cell therapy work in Benchling today, talk to us about evaluating BioPilot alongside it.
Yes. BioPilot is built for academic and translational cell therapy labs as well as biotech and pharma R&D teams, at a price point accessible to academic groups. Versioned protocols and linked records keep work reproducible as students, postdocs and collaborators come and go, and make results easier to compare, publish and hand over.
BioPilot is built to support 21 CFR Part 11 and EU GMP Annex 11 requirements for electronic records and signatures: immutable audit trails, e-signatures bound to each record, protocol locking with version control, and end-to-end material traceability. Evidence for IND and CTA submissions is captured during the work rather than reconstructed afterwards.
BioPilot applies Bayesian optimization to your experiment history to suggest which conditions to test next, such as dissolved oxygen, temperature, agitation or compound concentration, so teams reach robust protocols in fewer runs. Scientists stay in control and review every suggestion before it is run.
In Europe. BioPilot ApS is a Danish company. Your records and files are stored in Copenhagen, Denmark and Stockholm, Sweden, and the encrypted nightly backups in Nuremberg, Germany. Your data stays yours and is never used to train external AI models.
Sign-in takes a password and a code from an authenticator app, asked for on every new device and at least every 7 days. Each organization's data is kept separate, and changes to key records go into a tamper-evident audit trail, including changes made by BioPilot staff. Every night the database and all uploaded files are backed up to a second provider in Germany, encrypted before they leave our backup server; each backup is locked against deletion for at least 14 days and kept for 25 days, and every month we restore one to check it. The details are in our Data Processing Agreement.
Bring a protocol you run today. In a 30-minute call we walk you through it in BioPilot: its stages, its materials and the records it produces.
Or get BioPilot news by email